CCND1 and glioblastoma: Similarly, in the treatment of glioblastoma (GBM) and colorectal cancer using the multi-attenuated HSV-1 mutant G47D, TSA improved the antitumor effects synergistically, with cyclin D1 blockade and VEGF inhibition [138].